Hoth Therapeutics (NASDAQ:HOTH) Announces Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) posted its quarterly earnings data on Friday. The company reported ($0.17) earnings per share for the quarter, FiscalAI reports.

Hoth Therapeutics Trading Down 4.9%

NASDAQ:HOTH opened at $0.63 on Friday. The company has a market cap of $12.11 million, a price-to-earnings ratio of -0.79 and a beta of 0.57. Hoth Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.12. The stock has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $0.98.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HOTH shares. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Wednesday, March 25th. Wall Street Zen downgraded shares of Hoth Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Hoth Therapeutics in a research report on Friday, April 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Hoth Therapeutics currently has an average rating of “Hold” and an average price target of $5.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in shares of Hoth Therapeutics by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares in the last quarter. Virtu Financial LLC bought a new position in Hoth Therapeutics in the third quarter worth approximately $184,000. Citadel Advisors LLC purchased a new position in Hoth Therapeutics during the 3rd quarter worth $232,000. DRW Securities LLC purchased a new position in Hoth Therapeutics during the 4th quarter worth $257,000. Finally, Kestra Private Wealth Services LLC bought a new stake in Hoth Therapeutics during the 3rd quarter valued at $51,000. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.